Asia
Market Size in USD Billion
CAGR :
% 
USD
501.42 Million
USD
1,051.92 Million
2024
2032
 予測期間 |
2025 –2032 |
 市場規模（基準年） |
USD 501.42 Million |
 Market Size (Forecast Year) |
USD 1,051.92 Million |
 CAGR |
% |
| Major Markets Players |
|
Asia-Pacific Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market segmentation, By Product Type (Single Injection (Monophasic), Three-Injection Regimen (Triphasic), Five-Injection Regimen (Pentaphasic)), Formulation (Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid), Molecular Weight (High Molecular Weight (HMW) HA, Low Molecular Weight (LMW) HA, Intermediate Molecular Weight HA), Treatment Goals (Viscosupplementation, Anti-Inflammatory & Pain Reduction, Cartilage Protection & Regeneration), End User (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, Specialty Pain Management Centers), Distribution Channel (Direct Tender , Retail & Online Pharmacies, Others), Country (China, India, Japan, South Korea, Australia, Indonesia, Thailand, Malaysia, Vietnam. Philippines, Taiwan, Singapore, New Zealand, Philippines, Kazakhstan, Brunei, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2032
Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Size
- The Asia-Pacific hyaluronic acid market for knee osteoarthritis treatment market was valued at USD 501.42 million in 2024 and is expected to reach USD 1,051.92 million by 2032
- During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 9.8 %, primarily driven by the anticipated launch of therapies
- The rising prevalence of knee osteoarthritis and the growing preference for minimally invasive treatments are driving demand for hyaluronic acid-based therapies. Additionally, increasing awareness about the benefits of viscosupplementation is further propelling market growth.
Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Analysis
- Hyaluronic acid is a naturally occurring substance in the body, particularly in connective tissues, skin, and synovial fluid that lubricates joints. In the context of knee osteoarthritis treatment, hyaluronic acid is utilized as a viscosupplement to improve joint function and alleviate pain. By injecting hyaluronic acid directly into the knee joint, it can enhance the cushioning effect, reduce friction during movement, and promote the regeneration of cartilage, providing relief for individuals suffering from osteoarthritis symptoms. This treatment aims to restore mobility, improve quality of life, and delay the progression of the disease.
- Asia-Pacific emerges as a leading region in the Hyaluronic Acid Market for Knee Osteoarthritis Treatment, driven by its well-established healthcare system and high adoption of advanced, non-surgical joint care options.
- For instance, the U.S. shows strong uptake of intra-articular hyaluronic acid injections, supported by growing patient awareness and favorable reimbursement policies
- The region's focus on improving mobility and quality of life for osteoarthritis patients continues to drive innovation and market expansion in hyaluronic acid-based therapies.
Report Scope and Hyaluronic Acid Market for Knee Osteoarthritis Treatment Segmentation
|
Attributes |
Hyaluronic Acid Market for Knee Osteoarthritis Treatment Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Trends
“Growing Preference for Minimally Invasive and Targeted Therapies”
- A key trend in the Asia-Pacific hyaluronic acid market for knee osteoarthritis treatment is the increasing preference for minimally invasive, targeted treatment options.
- Hyaluronic acid injections, also known as viscosupplementation, offer localized pain relief and improved joint mobility without the need for surgical intervention, making them highly attractive to both patients and clinicians
- For instance, single and multi-injection formulations tailored to patient needs are gaining traction, offering flexibility and convenience in treatment regimens
- The trend is further supported by advancements in injection techniques, improved formulation stability, and extended duration of therapeutic effects.
- Additionally, the integration of imaging technologies such as ultrasound-guided injections enhances precision and patient comfort.
- This shift towards non-surgical, effective, and patient-centric treatment options is shaping the future of knee osteoarthritis care and fueling growth in the hyaluronic acid market.
Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Dynamics
Driver
“Increasing Prevalence of Knee Osteoarthritis”
- As the Asia-Pacific population increasingly comprises older adults, the prevalence of osteoarthritis, a degenerative joint condition characterized by the breakdown of cartilage, is expected to grow significantly. This growing demographic trend is particularly alarming since osteoarthritis leads to symptoms such as chronic pain, stiffness, and decreased mobility, which can severely impact the quality of life for individuals affected. The rising incidence of osteoarthritis is prompting a surge in the demand for effective treatment solutions, as many patients are seeking alternatives to invasive surgical options. Hyaluronic acid (HA) injections have emerged as a highly favored minimally invasive treatment option that effectively alleviates symptoms by providing lubrication to the affected joint, thus enhancing joint function and mobility.
- These injections work by supplementing the naturally occurring hyaluronic acid in the synovial fluid, reducing friction between joints and promoting better shock absorption. This dual action not only helps to relieve pain but also improves overall joint health, making HA an appealing choice for both patients and healthcare providers.
For instance,
- In December 2023, NCBI stated that studies continue to illustrate the high prevalence of OA worldwide, with a greater burden among older individuals, women, some racial and ethnic groups, and individuals with lower socioeconomic status. Modifiable risk factors for OA with the strongest evidence are obesity and joint injury
- 2024年11月、Frontiers誌に掲載された記事によると、インドの研究では、年齢層を問わずKOAの有病率が上昇していることが報告されており、50歳未満では19.2%、50～60歳では30.7%、60～70歳では39.7%、70歳以上では54.1%となっている(23)。別の研究では、55歳を過ぎると変形性膝関節症の有病率と発症率の両方が大幅に上昇することが明らかになった。55歳以上の人の平均有病率は13.2%で、男性では9.4%、女性では18.0%となっている。
- ヒアルロン酸の効能に対する認識の高まりは、医療従事者と患者双方におけるヒアルロン酸の導入を促進しています。臨床研究において、変形性膝関節症の患者の痛みを軽減し、生活の質を向上させるヒアルロン酸の有効性が実証され続けていることから、より多くの医療従事者がこれらの治療法を診療に取り入れています。こうしたヒアルロン酸の認知度向上と変形性膝関節症の症例増加は、市場の成長に好ましい環境を生み出し、メーカー間のイノベーションと競争を促進し、ヒアルロン酸療法のための高度な処方と投与方法の開発を促進しています。
機会
「ヒアルロン酸製剤と送達システムの進歩」
- 改良された高分子量・架橋ヒアルロン酸製品は、より持続的な鎮痛効果をもたらし、注射回数も少なくて済みます。これは、症状管理のための効果的かつ簡便なソリューションを求める患者にとって魅力的です。ハイドロゲルやナノ粒子システムといった革新的な送達方法は、関節におけるヒアルロン酸の耐久性と効果を高めます。これらの開発は、高齢化社会における高まる需要に応えています。企業はこれらの技術を活用することで、競争の激しい市場で差別化を図り、より多くの顧客を獲得することができます。治療頻度の低減と患者の転帰改善に重点を置くことで、市場の成長ポテンシャルが高まります。そのため、変形性膝関節症治療におけるヒアルロン酸分野は、投資と事業拡大にとって非常に魅力的な分野となっています。
例えば、
- IBSA Institut Biochimique SA、サノフィ、生化学工業株式会社によると、各社は関節の潤滑性、疼痛緩和、治療の持続性を高める独自の製剤を開発しています。これらの革新は、保持力の向上、架橋技術、そして患者の利便性に焦点を当てており、持続的な症状緩和を実現します。
- 2024年4月、ScienceDirectの記事では、変形性関節症の薬剤送達に用いられるヒアルロン酸ベースのリポソームにおいて、カップリング化学を用いたリポソーム調製後の表面機能化、または還元アミノ化によるヒアルロン酸-脂質複合体の合成が注目されました。これらの方法は、生体適合性を向上させ、様々な薬剤の同時送達を可能にし、複合体形成の制御性を高め、効果的な関節炎治療のためのリポソームシステムを最適化します。
- ヒアルロン酸製剤と送達システムの進歩は、変形性膝関節症治療の有効性と利便性を著しく向上させます。製品寿命の延長と注射頻度の低減により、これらのイノベーションは高齢化社会における低侵襲ソリューションへの高まる需要に応えます。これらの技術を採用する企業は、市場でのプレゼンスを強化し、より多くの患者を惹きつけ、業界の成長を捉えることができます。そのため、ヒアルロン酸をベースとした治療への投資は、進化する医療環境において長期的な成功を実現するための戦略的機会となります。
抑制/挑戦
「膝関節炎におけるヒアルロン酸療法のコスト関連の課題とアクセスに関する懸念」
- 変形性膝関節症に対するヒアルロン酸（HA）注射は、特に保険適用外、あるいは全額補償されない場合、非常に高額になることがあります。この経済的負担により、患者は自己負担を強いられることが多く、特に経済的に余裕のない患者にとっては大きな負担となる可能性があります。
- さらに、長期間にわたり複数回の注射が必要となる場合があり、治療費が増大します。その結果、痛みを軽減し関節機能を改善する可能性を秘めているにもかかわらず、患者はHA療法の開始を遅らせたり、完全に断念したりすることがあります。治療費の高額さと保険適用の少なさは、しばしばアクセスを制限し、治療の格差を生み出しています。こうした経済的課題への対処は、より多くの患者がHA療法を受けられるようにし、より多くの人々がこの効果的な膝関節症治療の恩恵を受けられるようにするために不可欠です。
例えば、
- 2024年2月、Pain Physician誌の調査結果によると、HA注射を受けた患者は、特に複数回の注射を受けた患者は、コルチコステロイド（CS）注射を受けた患者や注射を受けなかった患者と比較して、平均費用が著しく高かったことが示されています。さらに、人工膝関節全置換術（TKA）を受けた患者は、HA治療の費用が高く、この治療法に伴う経済的障壁が浮き彫りになっています。
- サノフィ、エノビス、ビオビコによると、Synvisc One（232.81米ドル）やBiolevox Ha（323.53米ドル）といった膝関節炎に対するヒアルロン酸（HA）療法は高額なため、アクセスが制限されています。多くの患者は、特に保険に加入していない場合は、治療費の支払いに苦労しています。これらの治療へのアクセスを改善するには、より低コストの選択肢、より広範な適用範囲、そして価格改革が不可欠です。
- ヒアルロン酸（HA）注射の高額な費用と保険適用の少なさは、多くの変形性膝関節症患者にとって大きな障壁となっています。複数回の注射が必要となることなど、こうした経済的な問題から、疼痛緩和と関節機能改善という効果が実証されているにもかかわらず、患者はHA療法の導入を延期したり、断念したりしてしまうことがよくあります。この治療法へのアクセスを向上させ、より多くの人々がその恩恵を受けられるようにするためには、こうした費用関連の課題に対処することが不可欠です。保険適用範囲の拡大と自己負担額の削減は、HA療法へのアクセスを向上させ、最終的には変形性膝関節症に苦しむ人々のケアの質の向上につながります。
膝関節炎治療におけるヒアルロン酸市場 市場展望
市場は、基礎タイプ、製品タイプ、吸収部位、年齢層、供給源、配送方法、性別、流通チャネルに基づいてセグメント化されています。
|
セグメンテーション |
サブセグメンテーション |
|
製品タイプ別 |
|
|
処方別 |
|
|
分子量別 |
|
|
治療目標別
|
|
|
エンドユーザー別 |
|
|
流通チャネル別 |
|
膝関節炎治療におけるヒアルロン酸市場：地域分析
「中国は、膝関節炎治療用ヒアルロン酸市場において、支配的かつ最も急速に成長している国です」
- 中国は、先進的な医療インフラ、非外科的関節療法の早期導入、そして主要な市場プレーヤーの強力な存在に支えられ、膝関節炎治療用のヒアルロン酸市場をリードしています。
- 中国は、膝関節炎の発症率の上昇、高齢者人口の増加、関節内ヒアルロン酸注射などの低侵襲治療の選好の増加により、大きな市場シェアを占めています。
- 有利な償還ポリシー、確立された規制枠組み、医療費の増加は、この地域の市場の成長にさらに貢献しています。
- さらに、患者の移動性と生活の質の向上に重点を置き、ヒアルロン酸製剤と投与技術の革新と相まって、アジア太平洋地域全体で市場拡大を推進し続けています。
膝関節炎治療におけるヒアルロン酸市場シェア
市場競争環境は、競合他社ごとに詳細な情報を提供します。企業概要、財務状況、収益、市場ポテンシャル、研究開発投資、新規市場への取り組み、アジア太平洋地域におけるプレゼンス、生産拠点・設備、生産能力、強みと弱み、製品投入、製品群の幅広さ、アプリケーションにおける優位性などの詳細が含まれます。上記のデータは、各社の市場への注力分野にのみ関連しています。
市場で活動している主要なマーケットリーダーは次のとおりです。
- LG化学（韓国）
- バイオベンタスLLC（米国）
- Seikagaku Corporation (Japan)
- サノフィ（フランス）
- アニカ・セラピューティクス社（米国）
- IBSA Biochemical Institute SA (スイス)
- ビアトリス（米国）
- ジマー・バイオメット（米国）
- フィディア・ファーマセウチSpA（イタリア）
- フェリング・ファーマシューティカルズ（スイス）
- TRB CHEMEDICA SA（スイス）
- 杭州星清医療製品有限公司（中国）
- ハンミ製薬株式会社（韓国）
- ヴィルショウ・バイオテック（インド）
- ユープラクシア・ファーマシューティカルズ（カナダ）
アジア太平洋地域における膝関節炎治療用ヒアルロン酸市場の最新動向
- 2024年7月、LG化学は中国の変形性関節症治療市場に参入しました。同社は易帆製薬と提携し、変形性関節症治療薬シノビアン注射剤を中国で発売しました。これにより、同社は市場参入を果たし、ポートフォリオを拡大することができました。
- ユープラクシア・ファーマシューティカルズは2023年5月、変形性関節症（OA）治療薬EP-104IARの第2相臨床試験における最後の患者来院を完了したと発表しました。同社は第2四半期にトップラインデータを発表する予定で、有意な疼痛緩和と患者機能の改善、そして有望な安全性プロファイルを示すことが期待されています。
- 2025年3月、IBSAは販売代理店のLunatusと提携し、サウジアラビアとUAEにおける変形性関節症治療の拡大を目指します。この戦略的提携は、疼痛管理ソリューションの強化を目的としており、変形性関節症患者における高度な治療への高まる需要に対応し、他の地域諸国にも拡大する可能性があります。
- 2023年6月、ユープラクシア・ファーマシューティカルズは、米国食品医薬品局（FDA）が膝関節炎（OA）治療薬EP-104IARにファストトラック指定を付与したことを発表しました。この指定は、開発と規制当局による審査を迅速化し、FDAとのやり取りを迅速化することを目指しています。同社は現在、第2相試験を進めており、トップラインデータは2023年第2四半期に得られる見込みです。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 AVERAGE SELLING PRICE (ASP) ANALYSIS
4.4 MICRO AND MACRO ECONOMIC FACTORS
4.5 KEY PRICING STRATEGIES
4.6 HEALTHCARE ECONOMY
4.7 PENETRATION AND GROWTH PROSPECT MAPPING
4.8 TECHNOLOGY ROADMAP
4.9 VALUE CHAIN ANALYSIS
5 COMPANY-WISE OVERVIEW OF INTRA-ARTICULAR HYALURONIC ACID (HA) INJECTION PRODUCTS BASED ON MOLECULAR WEIGHT -
6 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, REGULATORY FRAMEWORK
6.1 NORTH AMERICA
6.2 EUROPE
6.3 ASIA-PACIFIC
6.4 MIDDLE EAST AND AFRICA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF KNEE OSTEOARTHRITIS
7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE AND NON-SURGICAL TREATMENT OPTIONS
7.1.3 CLINICAL VALIDATION OF HYALURONIC ACID IN OSTEOARTHRITIS TREATMENT
7.1.4 RECENT LAUNCHES OF HYALURONIC ACID FOR OSTEOARTHRITIS TREATMENT
7.2 RESTRAINTS
7.2.1 COMPETITION OF ALTERNATIVE THERAPIES FOR KNEE OSTEOARTHRITIS
7.2.2 REGULATORY CHALLENGES FACED BY THE MANUFACTURERS IN THE HYALURONIC ACID MARKET
7.3 OPPORTUNITIES
7.3.1 ADVANCEMENTS IN HYALURONIC ACID FORMULATIONS AND DELIVERY SYSTEMS
7.3.2 RAISING AWARENESS AND ACCEPTANCE OF HYALURONIC ACID FOR KNEE OSTEOARTHRITIS TREATMENT AMONG PHYSICIANS AND PATIENTS
7.3.3 THE IMPACT OF COMBINING HYALURONIC ACID WITH OTHER THERAPEUTIC OPTIONS FOR KNEE OSTEOARTHRITIS
7.4 CHALLENGES
7.4.1 COST-RELATED CHALLENGES AND ACCESSIBILITY CONCERNS FOR HYALURONIC ACID THERAPY IN KNEE OSTEOARTHRITIS
7.4.2 SHORT-TERM BENEFITS WITH LIMITED LASTING EFFICACY OF HYALURONIC ACID FOR KNEE OA
8 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 SINGLE INJECTION (MONOPHASIC)
8.3 THREE-INJECTION REGIMEN (TRIPHASIC)
8.4 FIVE-INJECTION REGIMEN (PENTAPHASIC)
9 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION
9.1 OVERVIEW
9.2 CROSS-LINKED HYALURONIC ACID
9.3 NON-CROSS-LINKED HYALURONIC ACID
10 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT
10.1 OVERVIEW
10.2 HIGH MOLECULAR WEIGHT (HMW) HA
10.3 LOW MOLECULAR WEIGHT (LMW) HA
10.4 INTERMEDIATE MOLECULAR WEIGHT HA
11 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS
11.1 OVERVIEW
11.2 VISCOSUPPLEMENTATION
11.3 ANTI-INFLAMMATORY & PAIN REDUCTION
11.4 CARTILAGE PROTECTION & REGENERATION
12 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 ORTHOPEDIC CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 SPECIALTY PAIN MANAGEMENT CENTERS
13 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL & ONLINE PHARMACIES
13.4 OTHERS
14 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION
14.1 ASIA-PACIFIC
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 SOUTH KOREA
14.1.5 AUSTRALIA
14.1.6 SINGAPORE
14.1.7 THAILAND
14.1.8 INDONESIA
14.1.9 MALAYSIA
14.1.10 TAIWAN
14.1.11 NEW ZEALAND
14.1.12 PHILIPPINES
14.1.13 VIETNAM
14.1.14 KAZAKHSTAN
14.1.15 BRUNEI
14.1.16 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 LG CHEM
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 BIOVENTUS
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 SEIKAGAKU CORPORATION
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 ANIKA THERAPEUTICS, INC.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 EUPRAXIA PHARMACEUTICALS
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 FIDIA FARMACEUTICI S.P.A.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 FERRING
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO.,LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 HANMI PHARM.CO., LTD
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 IBSA INSTITUT BIOCHIMIQUE SA.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 TRB CHEMEDICA INTERNATIONAL SA
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENTS
17.13 VIATRIS INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 VIRCHOW BIOTECH
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 ZIMMER BIOMET
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 COMPANY PRODUCT AND ADVANCEMENT IN FORMULATION
TABLE 2 COMPANY PRODUCT AND COMBINATION THERAPY
TABLE 3 PRICE OF THE HYALURONIC ACID INJECTION
TABLE 4 COMPANY PRODUCT AND LASTING EFFICACY
TABLE 5 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC SINGLE INJECTION (MONOPHASIC) IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC THREE-INJECTION REGIMEN (TRIPHASIC) IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC FIVE-INJECTION REGIMEN (PENTAPHASIC IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC CROSS-LINKED HYALURONIC ACID IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC NON-CROSS-LINKED HYALURONIC ACID IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC HIGH MOLECULAR WEIGHT (HMW) HA IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC LOW MOLECULAR WEIGHT (LMW) HA IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC INTERMEDIATE MOLECULAR WEIGHT HA IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC VISCOSUPPLEMENTATION IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC ANTI-INFLAMMATORY & PAIN REDUCTION IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC CARTILAGE PROTECTION & REGENERATION IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC HOSPITALS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC ORTHOPEDIC CLINICS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC SPECIALTY PAIN MANAGEMENT CENTERS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC DIRECT TENDER IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC RETAIL & ONLINE PHARMACIES IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC OTHERS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 36 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 38 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 39 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 40 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 41 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 42 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 44 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 45 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 46 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 47 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 48 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 50 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 51 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 52 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 53 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 54 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 56 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 57 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 58 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 59 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 60 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 62 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 63 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 64 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 65 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 66 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 68 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 69 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 70 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 71 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 72 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 74 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 75 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 76 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 77 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 78 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 80 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 81 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 82 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 83 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 84 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 86 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 87 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 88 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 89 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 90 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 92 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 93 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 94 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 95 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 96 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 98 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 99 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 100 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 101 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 102 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 104 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 105 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 106 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 107 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 108 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 110 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 111 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 112 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 113 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 114 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 116 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 117 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 118 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 119 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 120 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 122 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 123 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 124 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 125 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 126 REST OF ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
図表一覧
FIGURE 1 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: SEGMENTATION
FIGURE 2 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: LIFELINE CURVE
FIGURE 7 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: SEGMENTATION
FIGURE 12 THREE SEGMENTS COMPRISE THE ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE
FIGURE 13 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 RISING PREVALENCE OF KNEE OSTEOARTHRITIS IS EXPECTED TO DRIVE THE GROWTH OF ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT FROM 2025 TO 2032
FIGURE 16 THE SINGLE INJECTION (MONOPHASIC) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT IN 2025 - 2032
FIGURE 17 DROC ANALYSIS
FIGURE 18 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY PRODUCT TYPE, 2024
FIGURE 19 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY PRODUCT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY PRODUCT TYPE, CAGR (2025-2032)
FIGURE 21 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY FORMULATION, 2024
FIGURE 23 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY FORMULATION, 2025-2032 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY FORMULATION, CAGR (2025-2032)
FIGURE 25 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY FORMULATION, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY MOLECULAR WEIGHT, 2024
FIGURE 27 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY MOLECULAR WEIGHT, 2025-2032 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY MOLECULAR WEIGHT, CAGR (2025-2032)
FIGURE 29 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY MOLECULAR WEIGHT, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY TREATMENT GOALS, 2024
FIGURE 31 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY TREATMENT GOALS, 2025-2032 (USD THOUSAND)
FIGURE 32 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY TREATMENT GOALS, CAGR (2025-2032)
FIGURE 33 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY TREATMENT GOALS, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY END USER, 2024
FIGURE 35 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 36 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY END USER, CAGR (2025-2032)
FIGURE 37 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY END USER, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY DISTRIBUTION CHANNEL, 2024
FIGURE 39 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 40 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 41 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: COMPANY SHARE 2024 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
